Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TIRRELL T JOHNSON

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1518042415
CMS profile
204048
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$230.02

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $230.02 3

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $110.05 1
Genentech USA, Inc. $87.82 1
AstraZeneca Pharmaceuticals LP $32.15 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TIRRELL T JOHNSON

NPI 1518042415 · CMS profile ID 204048

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518042415?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TIRRELL T JOHNSON, NPI 1518042415, CMS profile ID 204048. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518042415?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). TIRRELL T JOHNSON, NPI 1518042415, CMS profile ID 204048. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518042415?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
TIRRELL T JOHNSON, NPI 1518042415, CMS profile ID 204048, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1518042415?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $230.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $87.8211/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133126289 CMS
AstraZeneca Pharmaceuticals LP $32.1510/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104353462 CMS
Merck Sharp & Dohme LLC $110.0503/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141885607 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $11.92 1
PY2022 $12.94 1
PY2023 $367.61 7
PY2024 $230.02 3
PY2025 $303.63 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,665,235.05 404
PY2024 Principal investigator $475,494.74 62
PY2023 Principal investigator $95,270.20 17
PY2022 Principal investigator $226,118.71 15
PY2021 Principal investigator $31,342.00 7
PY2020 Principal investigator $82,456.06 7
PY2019 Principal investigator $37,669.74 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $58,389.20 12/31/2024 Covered Recipient Teaching Hospital
Orlando Health
A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOTE 158 No dispute reported 06/30/2026 1136409990
Principal investigator 2 Merck Sharp & Dohme LLC $129,632.72 12/31/2024 Covered Recipient Teaching Hospital
Orlando Health
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma INTerpath-001 No dispute reported 06/30/2026 1136437777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $83.84 12/26/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405176
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $53.71 12/26/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405178
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,784.12 12/26/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405180
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $379.90 12/26/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405182
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 12/26/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405184
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,426.12 12/26/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405186
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $73.36 12/26/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405188
Principal investigator 1 Janssen Research & Development, LLC $7,140.00 12/23/2024 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer No dispute reported 06/30/2026 1079009012
Principal investigator 1 Janssen Research & Development, LLC $3,080.00 12/23/2024 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer No dispute reported 06/30/2026 1079009032
Principal investigator 1 Daiichi Sankyo Inc. $1,082.70 12/18/2024 Non-covered Recipient Entity
Translational Research In Oncology Us Inc
DS1062-A-U301 No dispute reported 06/30/2026 1086073102
Principal investigator 1 Janssen Research & Development, LLC $27,163.00 12/16/2024 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer No dispute reported 06/30/2026 1079008982
Principal investigator 1 Janssen Research & Development, LLC $770.00 12/16/2024 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer No dispute reported 06/30/2026 1079008984
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 12/16/2024 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer No dispute reported 06/30/2026 1079008990
Principal investigator 1 ModernaTX, Inc. $1,403.01 12/13/2024 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma No dispute reported 06/30/2026 1147149818
Principal investigator 1 Daiichi Sankyo Inc. $794.00 12/05/2024 Non-covered Recipient Entity
Translational Research In Oncology Us Inc
DS1062-A-U301 No dispute reported 06/30/2026 1086073094
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $725.09 12/04/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405096
Principal investigator 1 Daiichi Sankyo Inc. $1,082.70 11/18/2024 Non-covered Recipient Entity
Translational Research In Oncology Us Inc
DS1062-A-U301 No dispute reported 06/30/2026 1086073090
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 11/14/2024 Non-covered Recipient Entity
Translational Research In Oncology Us Inc
DS1062-A-U301 No dispute reported 06/30/2026 1086073088
Principal investigator 1 ModernaTX, Inc. $4,873.20 11/06/2024 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma No dispute reported 06/30/2026 1147149816
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,299.05 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405038
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,784.12 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405040
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $379.90 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405042
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,784.12 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405044
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,716.94 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405046
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,557.12 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $334.05 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405050
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $379.90 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405052
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $334.05 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405054
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,299.05 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405056
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,784.12 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405058
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $379.90 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405060
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $379.90 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405062
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,784.12 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405064
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,716.94 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405066
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,784.12 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405068
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $379.90 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405070
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,557.12 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405072
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,784.12 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405074
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $334.05 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405076
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $379.90 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405078
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $334.05 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405080
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,299.05 10/25/2024 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1082405082
Principal investigator 1 ModernaTX, Inc. $2,252.48 10/21/2024 Covered Recipient Teaching Hospital
Orlando Health
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1147149950
Principal investigator 1 ModernaTX, Inc. $7,151.81 10/16/2024 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma No dispute reported 06/30/2026 1147149812
Principal investigator 1 ModernaTX, Inc. $1,000.00 10/03/2024 Covered Recipient Teaching Hospital
Orlando Health
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1147149948
Principal investigator 1 ModernaTX, Inc. $9,746.40 10/02/2024 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma No dispute reported 06/30/2026 1147149814
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/18/2024 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma No dispute reported 06/30/2026 1147149774
Principal investigator 1 Janssen Research & Development, LLC $294.00 08/22/2024 Covered Recipient Teaching Hospital
Orlando Health
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta No dispute reported 06/30/2026 1079009002
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $39,272.00 08/12/2024 Covered Recipient Teaching Hospital
Orlando Health
Ph II/III IO Naive Mel (lag3 + nivo FDC) - A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma No dispute reported 06/30/2026 1123473993
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 08/08/2024 Non-covered Recipient Entity
Regional Cancer Care Associates Admin Office
DS1062-A-U301 No dispute reported 06/30/2026 1086069362
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $569.07 06/26/2024 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
PhI in 1L SCLC with BI 764532 + chemo plus anti PD-L1 No dispute reported 06/30/2026 1155144986
Principal investigator 1 Janssen Research & Development, LLC $170.00 05/24/2024 Covered Recipient Teaching Hospital
Orlando Health
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta No dispute reported 06/30/2026 1079009008
Principal investigator 1 PFIZER INC. $7,540.00 05/09/2024 Covered Recipient Teaching Hospital
Orlando Health
A PHASE 2 STUDY OF CONTINUOUS TALAZOPARIB PLUS INTERMITTENT LOWDOSE TEMOZOLOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY EXTENSIVESTAGE SMALL CELL LUNG CANCER TRIOUS L07 No dispute reported 06/30/2026 1131035310
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 04/18/2024 Non-covered Recipient Entity
Translational Research In Oncology Us Inc
DS1062-A-U301 No dispute reported 06/30/2026 1086073070
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $89,309.10 03/25/2024 Covered Recipient Teaching Hospital
Orlando Health
PhI in 1L SCLC with BI 764532 + chemo plus anti PD-L1 No dispute reported 06/30/2026 1101069391
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 01/29/2024 Non-covered Recipient Entity
Translational Research In Oncology Us Inc
DS1062-A-U301 No dispute reported 06/30/2026 1086073060
Principal investigator 1 Janssen Research & Development, LLC $11,618.00 01/26/2024 Covered Recipient Teaching Hospital
Orlando Health
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta No dispute reported 06/30/2026 1079008980
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,090.46 01/25/2024 Non-covered Recipient Entity
Orlando Health Medical Group Inc
PhI in 1L SCLC with BI 764532 + chemo plus anti PD-L1 No dispute reported 06/30/2026 1101069111
Principal investigator 1 Janssen Research & Development, LLC $1,787.00 01/22/2024 Covered Recipient Teaching Hospital
Orlando Health
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta No dispute reported 06/30/2026 1079008974
Principal investigator 1 Daiichi Sankyo Inc. $930.17 01/18/2024 Non-covered Recipient Entity
Translational Research In Oncology Us Inc
DS1062-A-U301 No dispute reported 06/30/2026 1086073048